Thrombus Migration After Tenecteplase Versus Alteplase in Acute Large Vessel Occlusion
Lu Wang, Fuxia Yang, Xiao Wu, Lulan Li, Xueqiao Jiao, Fangfang Zhang, Fengyuan Che, Hongxing Han, Weidong Liu, Peifu Wang, Xuesong Li, Junfeng Shi, Jia Liu, Xunming Ji, Xiuhai Guo · 2026
Read Thrombus Migration After Tenecteplase Versus Alteplase in Acute Large Vessel Occlusion by Lu Wang, Fuxia Yang, Xiao Wu, Lulan Li, Xueqiao Jiao, Fangfang Zhang, Fengyuan Che, Hongxing Han, Weidong Liu, Peifu Wang, Xuesong Li, Junfeng Shi, Jia Liu, Xunming Ji, Xiuhai Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13243849.txt.
Description
Lu Wang and a large team compare two clot-busting drugs for major stroke in a 2026 study. After vein treatment, a clot in a large brain artery can dissolve, move downstream, or stay put. Whether the newer drug tenecteplase moves clots more than alteplase was unknown.
The team reviewed patients treated from 2022 to 2024 and matched 373 patients per drug. Clots moved more often after tenecteplase, and the edge was clear only when vessel opening began within an hour. Patients whose clots moved also regained independence more often at three months. Tenecteplase users likewise did better overall. The findings link early clot movement to better recovery.
Catalog record
| CREATOR | Lu Wang, Fuxia Yang, Xiao Wu, Lulan Li, Xueqiao Jiao, Fangfang Zhang, Fengyuan Che, Hongxing Han, Weidong Liu, Peifu Wang, Xuesong Li, Junfeng Shi, Jia Liu, Xunming Ji, Xiuhai Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |